Free Trial Free TrialFree Trial

More results...

Filter by Content types
Regulatory databases
Regulatory reports
Market reports
News analysis
Filter by Geography
Africa
Asia
Australasia
Europe
United Kingdom
North America
United States
South America

Alerts LATEST ALERTS

  • United States - Washington Pre-employment cannabis testing set to become illegal…
  • Europe CBD and cosmetics – EU working group works on…
  • Belgium Cannabinoid pouches banned by decree…
  • Delaware - United States Senate approves legal framework for adult possession of cannabis…
  • United States - Virginia Cannabis advertising becomes a Class 1 misdemeanour…
  • Kazakhstan ‘Narcotic’ cannabis banned from medical use by decree…
  • Canada Consultation opens on possible changes to cannabis regulations…
  • Turkey Grain Board takes over responsibility for cannabis growing…
  • Georgia US - United States Limit on medical cannabis licences raised…
  • Mississippi - United States Topical hemp products exempted from medical cannabis rules…
  • North Dakota - United States Medical cannabis bill relating to hospice care signed by governor…
  • Lithuania THC to be banned in all tobacco products as of 1st April…
View all
Blogs

Is the argument against classing CBD as a narcotic quite as clear-cut as they say?

Written by || 11th September 2020 || Blogs | Regulation and legislation |

What should the industry make of the recent paper from 11 industry associations putting forward a unified position on the issues surrounding the potential for CBD to be considered a narcotic? A ...

Restricted content. Do you want to read more?

Read our latest free content
Yellow card offence – but comments are a long way from being a dismissal of CBD
Mayhem in Mexico as agency grants firm hemp licence then vows to take it back
Relaxation beats intoxication – IHDC sales aren’t just about getting high
Spannabis: a celebration of the cannabis sector despite lingering uncertainties
Trulieve ends 2022 with over $1bn in revenue, 25 new dispensaries in the US
22nd Century’s cannabinoid division helps the company to double revenue

CannIntelligence.com provides independent, in-depth regulatory and market data and intelligence for the global cannabis and cannabinoid sector.

© 2023 Tamarind Media Limited (T/A CannIntelligence)
CannIntelligence does not provide legal, strategic or investment advice. Tamarind Media Limited, the publisher of CannIntelligence, does not accept any liability or responsibility for information or views published.